Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (MCF-7) in nude mice

Clinical Cancer Research

Volumn 10, Issue 22, 2004, Pages 7703-7711

  Chen, Jianmin ^a   Hui, Evon ^a   Ip, Terence ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA FRAGMENT; ESTRADIOL; KI 67 ANTIGEN; TAMOXIFEN;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DIET; FEMALE; IMMUNOHISTOCHEMISTRY; LINSEED; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME;

ANIMAL FEED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BODY WEIGHT; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DIET; ESTRADIOL; ESTROGENS; FEMALE; FLAX; HUMANS; KI-67 ANTIGEN; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, CHEMICAL; NEOPLASMS; ORGAN SIZE; SEEDS; TAMOXIFEN; TIME FACTORS; UTERUS;

EID: 9344238812     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1130     Document Type: Article

References (49)

1. Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutr Cancer 1991;16:43-52.
2. Cunnane SC. Dietary sources and metabolism of α-linolenic acid. In: Thompson LU, Cunnane SC, editors. Flaxseed in Human Nutrition, 2nd editon. Champaign, IL: AOCS Press; 2003. p. 63-91.
3. Thompson LU. Flaxseed, lignans, and cancer. In: Thompson LU, Cunnane SC, editors. Flaxseed in Human Nutrition, 2nd edition. Champaign IL: AOCS Press; 2003. p. 194-222.
4. Bougnoux P, Chajes V. α-Linolenic acid and cancer. In: Thompson LU, Cunnane SC, editors. Flaxseed in Human Nutrition, 2nd edition. Champaign, IL: AOCS Press; 2003. p. 233-44.
5. Serraino M, Thompson LU. The effect of flaxseed supplementation on early risk markers for mammary carcinogenesis. Cancer Lett 1991; 60:135-42.
6. Serraino M, Thompson LU. The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. Nutr Cancer 1992;17:153-9.
7. Thompson LU, Rickard SE, Orcheson LJ, Seidl M. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis (Lond) 1996;17:1373-6.
8. Thompson LU, Li T, Chen J, Goss PE. Biological effects of flaxseed in patients with breast cancer (abstract). Breast Cancer Res Treat 2000; 64:50.
9. Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 2002;185:31-7.
10. Chen J, Stavro PM, Thompson LU. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 2002;43:187-92.
11. Thompson LU, Seidl MM, Rickard SE, Orcheson LJ, Fong H. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 1996;26:159-65.
12. Jordan VC. The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 2001;949:72-9.
13. MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998;50:151-96.
14. VandeCreek L, Rogers E, Lester J. Use of alternative therapies among breast cancer outpatients compared with the general population. Altern Ther Health Med 1999;5:71-6.
15. Gotoh T, Yamada K, Ito A, Yin H, Kataoka T, Dohi K. Chemo-prevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and combination. Jpn J Cancer Res 1998; 89:487-95.
16. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474-7.
17. Saarinen N, Makela S, Santi R. Mechanisms of anticancer effects of lignans with special emphasis on breast cancer. In: Thompson LU, Cunnane SC, editors. Flaxseed in Human Nutrition, 2nd edition. Champaign, IL: AOCS Press; 2003. p. 223-31.
18. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-77.
19. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN, Bouchier-Hayes DJ. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001;27:714-8.
20. Marson LP, Kurian KM, Miller WR, Dixon JM. The effect of tamoxifen on breast tumour vascularity. Breast Cancer Res Treat 2001; 66:9-15.
21. Charlier C, Chariot A, Antoine N, Merville MP, Gielen J, Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor negative MDA MB 435 cells. Biochem Pharmacol 1995; 49:351-8.
22. Buzdar AU. Data from the Årimidex, Tamoxifen, Alone or in Combination (ATAC) Trial: implications for use of aromatase inhibitors in 2003. Clin Cancer Res 2004;10:355S-61S.
23. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-51.
24. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells, Nutr Cancer 1997;28:236-47.
25. Welshons WV, Murphy CS, Koch R, Calaf G, Jordan VC. Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol. Breast Cancer Res Treat 1987;10:169-75.
26. Mousavi Y, Adlercreutz H. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 1992;41:615-9.
27. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 1974;249: 5373-8.
28. Wang C, Makela T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994;50:205-12.
29. Adlercreutz H, Bannwart C, Wahala K, et al. Inhibition of human aromatase by mammalian lignans and isoflavonoids phytoestrogens. J Steroid Biochem Mol Biol 1993;44:147-53.
30. Brooks JD. Phytoestrogens as modulators of estrogen metabolism [thesis], Toronto, Canada: University of Toronto; 2003.
31. Gupta M, McDougal A, Safe S. Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol 1998;67:413-9.
32. Brooks JD, Ward WE, Lewis JE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. Am J Clin Nutr 2004;79:318-25.
33. Haggans CJ, Travelli EJ, Thomas W, Martini MC, Slavin JL. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. Cancer Epidemiol Biomark Prev 2000;9:719-25.
34. Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer 1999;33:188-95.
35. Power KA, Saarinen NM, Chen J, Thompson LU. Lignans (enterolactone and enterodiol) negate the proliferative effect of isoflavone (genistein) on MCF-7 breast cancer cells in vitro and in vivo (abstract). Proc AACR 2004;45:878.
36. Rickard SE, Yuan YV, Thompson LU. Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett 2000;161: 47-55.
37. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-10.
38. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 2003;57:447-51.
39. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12:362-7.
40. Wakeling AE, Nicholson RI, Gee JM. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res 2001;7:4350S-5S.
41. Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:2690-4.
42. Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003;63: 8742-8.
43. Stoll BA. n-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 2002;87:193-8.
44. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 1997;66:1513S-22S.
45. Rose DP. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 1997;216:224-33.
46. El-Sohemy A, Archer MC. Regulation of mevalonate synthesis in rat mammary glands by dietary n-3 and n-6 polyunsaturated fatty acids. Cancer Res 1997;57:3685-7.
47. DeGraffenried LA, Friedrichs WE, Fulcher L, et al. Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity. Ann Oncol 2003;14:1051-6.
48. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Laurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas 1995:21:103-13.
49. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25.